The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy

Prenatal Diagnosis

Volumn 25, Issue 10, 2005, Pages 927-929

  Spencer, Kevin ^a,b   Cicero, Simona ^a,b   Atzei, Alessia ^b   Otigbah, Chineze ^a   Nicolaides, Kypros H ^b  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Free human chorionic gonadotrophin; Nuchal translucency; Pregnancy associated plasma protein A; Prenatal screening; Trisomy 21

Indexed keywords

BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ANEUPLOIDY; ARTICLE; BODY WEIGHT; CHROMOSOME ABERRATION; CONTROLLED STUDY; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MATERNAL SERUM; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; TRISOMY 21;

ANEUPLOIDY; BODY WEIGHT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DIABETES MELLITUS, TYPE 1; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; REFERENCE VALUES; ULTRASONOGRAPHY, PRENATAL;

EID: 27144483434     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1229     Document Type: Article

References (17)

1. Bartha JL, Wood J, Kyle PM, Soothill PW. 2003. The effect of metabolic control on fetal nuchal translucency in women with insulin-dependent diabetes: a preliminary study. Ultrasound Obstet Gynecol 21: 451-454.
2. Baumgarten A, Robinson J. 1988. Prospective study of inverse relationship between maternal glycosylated hemoglobin and serum alpha-fetoprotein concentrations in pregnant women with diabetes. Am J Obstet Gynecol 159: 77-81.
3. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. 2002. One stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15030 pregnancies. Ultrasound Obstet Gynecol 20: 219-225.
4. Huttly W, Rudnicka A, Wald NJ. 2004. Second trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn 24: 804-807.
5. Martin AO, Dempsey LM, Minogue J, et al. 1990. Maternal serum alpha-fetoprotein levels in pregnancies complicated by diabetes: implications for screening programs Am J Obstet Gynecol 163: 1209-1216.
6. +6 weeks: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25: 221-226.
7. Ong CYT, Liao A, Spencer K, Munim S, Nicolaides KH. 2000. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications Br J Obstet Gynaecol 107: 1265-1270.
8. Pedersen JF, Sorensen S, Molsted-Pedersen L. 1998. Serum levels of human placental lactogen, pregnancy associated plasma protein A and endometrial secretory protein PP14 in first trimester of diabetic pregnancy. Acta Obstet Gynecol Scand 77: 155-158.
9. Reece EA, Davis N, Mahoney MJ, Baumgarten A. 1987. Maternal serum alpha-fetoprotein in diabetic pregnancy: correlation with blood glucose control. Lancet 8553: 275.
10. Sancken U, Bartels I. 2001. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)? Prenat Diagn 21: 383-386.
11. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. A multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 18: 519-521.
12. Spencer K, Nicolaides KH. 2002. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 22: 877-879.
13. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotrophin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
14. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 107: 1271-1275.
15. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003a. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic: a review of three years prospective experience. Br J Obstet Gynaecol 110: 281-286.
16. Spencer K, Bindra R, Nicolaides KH. 2003b. Maternal weight correction of maternal serum PAPP-A and free β-hCG when screening for trisomy 21 in the first trimester rof pregnancy. Prenat Diagn 23: 851-855.
17. Spencer K, Bindra R, Nix ABJ, Heath V, Nicolaides KH. 2003c. Delta NT or NT MoM: which is the most appropriate for calculating accurate patient specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22: 142-148.